8-K ·Filed May 6, 2026

XNCR

Xencor Inc
BEARISH
Impact 7/10
Horizondays Processed4mo ago SEC0001326732-26-000042
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The sharp revenue drop and widened loss will likely pressure XNCR shares near-term. Key catalysts remain XmAb819 data in 2H26 and XmAb412 trial start in 3Q26. Monitor cash burn trajectory and any partnership milestone updates.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
XNCR ▲ +57.60% at T+60d
SHORT call ✗ call lost -57.60% · α vs SPY -53.76% · entry $12.31 → $19.40
Entry anchored
May 6, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α +0.83%
$12.31
settled 5mo ago
T+5d
+0.57%
call -0.57% · α +0.94%
$12.38
settled 5mo ago
T+20d
-7.23%
call +7.23% · α +10.37%
$11.42
settled 4mo ago
T+60d
+57.60%
call -57.60% · α -53.76%
$19.40
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Xencor reported Q1 2026 revenue of $4.5M (down 86% YoY) and a net loss of $128.9M ($1.71 per share), massively missing consensus estimates of a $0.65 loss per share. The quarter lacked milestone revenue that boosted prior-year results, and cash burn remains high, with year-end cash guidance lowered to $380-400M.

Key Financial Metrics

EPS
$-1.71
est $-0.65 · -163.1%
Revenue
$4.5M
-86.2% YoY
Rating
strong miss

Key Facts

  • Q1 2026 revenue fell 86% YoY to $4.5M from $32.7M
  • EPS of -$1.71 missed consensus estimate of -$0.65 (-163% surprise)
  • Net loss widened to $128.9M from $48.4M in Q1 2025
  • Cash and securities decreased to $541.8M from $610.8M at year-end 2025
  • Year-end 2026 cash guidance lowered to $380-400M from prior $400-430M
  • Pipeline milestones on track (XmAb819 expansion data 2H26, XmAb412 FIH 3Q26)

Financial Impact

Revenue decline of $28.2M YoY; net loss increase of $80.5M; EPS miss of $1.06 vs consensus

revenueepsnet incomecash guidance

Risk Factors

  • Lowered cash guidance signals higher than expected burn or delayed milestones
  • Dependence on partnership milestones for meaningful revenue
  • Clinical trial delays or negative data could further pressure valuation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326732-26-000042
Document: xncr-20260506.htm0001326732-26-000042
Document: 0001326732-26-000042-index-headers.html0001326732-26-000042
Document: 0001326732-26-000042-index.html0001326732-26-000042
Document: 0001326732-26-000042.txt0001326732-26-000042
8-K Data (Synthetic)0001326732-26-000042
10 reports for XNCR
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +67.24%May 5, 2026
Filters
Rows
Reports for XNCR — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
8-K
BULLISH ★ 7/10
$20.00 $26.62▲ +33.10%▲ +32.50%$24.84 (+24.20%)
Jun 17, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$12.64 $14.95▲ +18.28%▲ +17.74%$24.84 (+96.52%)
Jun 15, 2026
15w ago
144
NEUTRAL ★ 2/10
$12.21 $14.96▲ +22.52%▲ +23.27%$24.84 (+103.44%)
Jun 15, 2026
15w ago
144
NEUTRAL ★ 2/10
$12.21 $14.96▲ +22.52%▲ +23.27%$24.84 (+103.44%)
May 6, 2026
21w ago
8-K
BEARISH ★ 7/10
$12.31 $11.42▲ +7.23%▲ +10.37%$24.84 (−101.79%)
May 5, 2026
21w ago
8-K
BULLISH ★ 7/10
$12.85 $11.21▼ −12.76%▼ −17.72%$24.84 (+93.31%)
Apr 27, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$12.15 $11.63▼ −4.28%▼ −9.75%$24.84 (+104.44%)
Mar 5, 2026
30w ago
Insider Cluster
NEUTRAL ★ 3/10
$11.16 $12.81▲ +14.78%▲ +18.57%$24.84 (+122.58%)
Mar 4, 2026
30w ago
8-K
BEARISH ★ 8/10
$11.16 $12.81▼ −14.78%▼ −18.57%$24.84 (−122.58%)
Feb 25, 2026
31w ago
8-K
BULLISH ★ 7/10
$11.98 $12.40▲ +3.51%▲ +8.74%$24.84 (+107.35%)
Showing 10 of 10

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access